Palonosetron

Evidence Level: L5

Predicted Indications: 4

Palonosetron

Pharmacist Assessment Report

Palonosetron: From Chemotherapy-Induced Nausea and Vomiting to Migraine Disorder

One-Sentence Summary

Palonosetron is a 5-HT3 receptor antagonist, a class of antiemetic used to prevent nausea and vomiting, and it is marketed in Australia as an injection. The TxGNN model predicts it may be effective for migraine disorder, but no clinical trials and only 1 case report (describing palonosetron causing migraine-type headache) are linked to this prediction. The evidence is model prediction only and does not currently support therapeutic use.

Quick Overview

Item	Content
Original Indication	Not recorded in the data compiled for this report (the registered Australian entry has no indication text). Literature identifies the established use as prevention of chemotherapy-induced nausea and vomiting (CINV)
Predicted New Indication	Migraine disorder
TxGNN Prediction Score	0.9974
Evidence Level	L5
Australia Market Status	Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items	1 (valid: 1)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Based on known information, palonosetron is a second-generation 5-HT3 receptor antagonist. Its efficacy in preventing chemotherapy-induced nausea and vomiting has been shown in phase 3 trials, and mechanistically it may be applicable to migraine, which involves serotonin signalling and prominent nausea.

The TxGNN score is very high (0.9974), but this should be read cautiously. The only linked publication reports palonosetron inducing migraine-type headache, which is a safety signal in the opposite direction to benefit. 5-HT3 antagonists have a plausible but unproven role in migraine and nausea pathways, and no clinical evidence supports palonosetron for migraine treatment or prevention.

Other predictions from the model (for example migraine with brainstem aura, trigeminal autonomic cephalalgia, headache disorder, glaucoma, sciatic neuropathy, and rare skin disorders) also have no supporting trials. Most appear to be TxGNN model (deep learning) artefacts, likely driven by proximity to the migraine node.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
21132477	2011	Case report	Can J Anaesth	Palonosetron-induced migraine-type headache (an adverse effect, not a benefit)

For the broader headache-related prediction, the linked publications are CINV studies in which headache was reported as an adverse event, not studies of headache treatment. They are not evidence of efficacy in migraine.

Australia Market Information

ARTG Number	Product Name	Dosage Form	Approved Indication
ARTG 5295Q	Palonosetron Dr.Reddy’s	Injection 250 micrograms (as hydrochloride) in 5 mL	Not available in the data compiled

Safety Considerations

Drug Interactions: The interaction screen returned 100 interacting drugs (the first 20 were reviewed). Major-level interactions include:
- Opioids and related analgesics: fentanyl, alfentanil, tramadol, dextromethorphan
- Triptans: sumatriptan, almotriptan
- QT-prolonging or cardiac drugs: amiodarone, amisulpride, amitriptyline, anagrelide
- Moderate-level interactions include abiraterone, dihydrocodeine, codeine, famotidine, formoterol, adenosine, salbutamol, alfuzosin, propofol and loperamide.
Relevant to this prediction: Triptans, the standard acute migraine treatments, appear among the major interactions, which would matter in any migraine use. A 2026 review also highlights QT prolongation as a class concern for antiemetics (PMID 42748473).

Please refer to the TGA-approved Product Information (PI) for warnings and contraindications.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction rests on a model score alone (evidence level L5). The only linked literature describes palonosetron causing migraine-type headache, which argues against benefit. There are no trials, and no mechanistic data are available.

To proceed, the following is needed:

Mechanism of action data (for example from DrugBank) and a clear mechanistic rationale for migraine
The TGA Product Information, to complete warnings, contraindications and the approved indication
Preclinical or early clinical evidence of efficacy in migraine that addresses the reported headache signal
A review of interaction risk with triptans and QT-prolonging drugs
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.